Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zenas BioPharma (ZBIO) EPS (Weighted Average and Diluted) (2023 - 2025)

Zenas BioPharma has reported EPS (Weighted Average and Diluted) over the past 3 years, most recently at -$5.17 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$5.17 for Q4 2025, down 130.52% from a year ago — trailing twelve months through Dec 2025 was -$8.44 (up 72.05% YoY), and the annual figure for FY2025 was -$8.44, up 29.02%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$5.17 at Zenas BioPharma, down from -$1.22 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ZBIO hit a ceiling of $16.94 in Q4 2024 and a floor of -$24.23 in Q2 2024.
  • Median EPS (Weighted Average and Diluted) over the past 3 years was -$3.14 (2024), compared with a mean of -$5.27.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 205.61% in 2024, while the deepest fall reached 356.12% in 2024.
  • Zenas BioPharma's EPS (Weighted Average and Diluted) stood at -$16.04 in 2023, then surged by 205.61% to $16.94 in 2024, then plummeted by 130.52% to -$5.17 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$5.17 (Q4 2025), -$1.22 (Q3 2025), and -$1.25 (Q2 2025) per Business Quant data.